Kaye Edward M. MD's Form 4 filing
Stoke Therapeutics, Inc. (STOK) · filed Mar 20, 2025
- Accession no.
- 0001415889-25-008711
- Filed
- Mar 20, 2025
- Trade date
- Mar 18-20, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 2 derivative transactions. Open-market sales total $163.7K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Kaye Edward M. MDCIK 0001522780 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 18, 2025 | Common Stock | SSaleDisposed | −10,382 | $8.67 | −$90,011.94 | 148,253 | Direct | |
| Mar 19, 2025 | Common Stock | SSaleDisposed | −8,907 | $8.27 | −$73,660.89 | 139,346 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 20, 2025 | Common Stock | AGrant or awardAcquired | +216,000 | $0.00 | $0 | 216,000 | Direct | |
| Mar 20, 2025 | Common Stock | AGrant or awardAcquired | +144,000 | $0.00 | $0 | 144,000 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.